Recent advances in the CRISPR genome editing tool set

Cited 83 time in scopus
Metadata Downloads

Full metadata record

DC FieldValueLanguage
dc.contributor.authorSu Bin Moon-
dc.contributor.authorDo Yon Kim-
dc.contributor.authorJeong Heon Ko-
dc.contributor.authorYong Sam Kim-
dc.date.accessioned2020-02-07T16:30:25Z-
dc.date.available2020-02-07T16:30:25Z-
dc.date.issued2019-
dc.identifier.issnI000-0028-
dc.identifier.uri10.1038/s12276-019-0339-7ko
dc.identifier.urihttps://oak.kribb.re.kr/handle/201005/19113-
dc.description.abstractGenome editing took a dramatic turn with the development of the clustered regularly interspaced short palindromic repeats (CRISPR)-CRISPR-associated proteins (Cas) system. The CRISPR-Cas system is functionally divided into classes 1 and 2 according to the composition of the effector genes. Class 2 consists of a single effector nuclease, and routine practice of genome editing has been achieved by the development of the Class 2 CRISPR-Cas system, which includes the type II, V, and VI CRISPR-Cas systems. Types II and V can be used for DNA editing, while type VI is employed for RNA editing. CRISPR techniques induce both qualitative and quantitative alterations in gene expression via the double-stranded breakage (DSB) repair pathway, base editing, transposase-dependent DNA integration, and gene regulation using the CRISPR-dCas or type VI CRISPR system. Despite significant technical improvements, technical challenges should be further addressed, including insufficient indel and HDR efficiency, off-target activity, the large size of Cas, PAM restrictions, and immune responses. If sophisticatedly refined, CRISPR technology will harness the process of DNA rewriting, which has potential applications in therapeutics, diagnostics, and biotechnology.-
dc.publisherSpringer-Nature Pub Group-
dc.titleRecent advances in the CRISPR genome editing tool set-
dc.title.alternativeRecent advances in the CRISPR genome editing tool set-
dc.typeArticle-
dc.citation.titleExperimental and Molecular Medicine-
dc.citation.number11-
dc.citation.endPage130-
dc.citation.startPage130-
dc.citation.volume51-
dc.contributor.affiliatedAuthorSu Bin Moon-
dc.contributor.affiliatedAuthorDo Yon Kim-
dc.contributor.affiliatedAuthorJeong Heon Ko-
dc.contributor.affiliatedAuthorYong Sam Kim-
dc.contributor.alternativeName문수빈-
dc.contributor.alternativeName김도연-
dc.contributor.alternativeName고정헌-
dc.contributor.alternativeName김용삼-
dc.identifier.bibliographicCitationExperimental and Molecular Medicine, vol. 51, no. 11, pp. 130-130-
dc.identifier.doi10.1038/s12276-019-0339-7-
dc.description.journalClassY-
Appears in Collections:
Synthetic Biology and Bioengineering Research Institute > Genome Editing Research Center > 1. Journal Articles
Files in This Item:
  • There are no files associated with this item.


Items in OpenAccess@KRIBB are protected by copyright, with all rights reserved, unless otherwise indicated.